biosim, the Spanish Association of Biosimilar Medicines, has announced the incorporation of Biocon Biologics as a new member of its General Assembly. His arrival has meant that the Employers' Association currently has 15 associated companies that largely represent the sector that researches, develops, produces or markets biosimilar medicines in Spain.
In the words of encarna cruz, CEO of BioSim, 'We are pleased to welcome Biocon Biologics as a new member of BioSim. The addition of a company committed to developing biosimilars reinforces our mission to expand access to safe, effective and affordable biological therapies for patients. Biocon Biologics has demonstrated a strong commitment to quality and sustainability, and we are confident that their experience and vision will bring great value to our Partnership.'
For its part, Joaquín Rodrigo, president of the employers' association, has stressed that 'The biosimilar market is at a crucial moment of expansion. While some biosimilar molecules continue to gain ground and consolidate their penetration, others have only recently entered the market following the loss of exclusivity of original molecules with a high economic impact. The expansion of biosimilars is increasingly notable, and having members such as Biocon Biologics is essential to strengthen the message that we want to convey from the industry: to involve all agents in the sector, including healthcare professionals, administrations, patients and citizens. From BioSim, we will continue to promote an open dialogue that favors a more efficient and sustainable healthcare system, where patient access to biological medicines is more agile.'
José Ramón López, Country Manager of Biocon Biologics Spain, added:“Biocon Biologics is pleased to become a member of BioSim, an association that does commendable work in Spain when representing “We are committed to providing a global, long-term, and innovative solution to the biosimilar industry and raising awareness of the medical benefits of these essential medicines. Since establishing its presence in Spain in 2023, Biocon Biologics has facilitated patient access to the treatment of oncological, autoimmune diseases, and diabetes. The collaboration between Biocon Biologics and BioSim, and more broadly with the biosimilar community in Spain, marks an important milestone in our goal to support healthcare professionals in their daily work and ensure the best possible care for patients. We are proud to continue to reinforce these objectives with our work, and with the commitment to contribute to the sustainability of the Spanish healthcare system.”
www.pharmatech.es/noticias/20241030/biocon-biologics-se-une-como-nuevo-miembro-de-biosim
